Designing a Phase 1 Single- and Multiple-Ascending-Dose Study of a Humanized Anti-APRIL Monoclonal Antibody in Healthy Adults: Starting-Dose Derivation, Escalation, and Protocol Synopsis

A humanized antibody that neutralizes a proliferation-inducing ligand (APRIL) is designed to reduce pathogenic immunoglobulin production in B-cell-driven diseases, and its first-in-human study must show that the starting dose sits well below any dose that could cause harm to a healthy volunteer. This article develops a hypothetical Phase 1 randomized, double-blind, placebo-controlled study with a single-ascending-dose part (four cohorts) and a multiple-ascending-dose part (two cohorts dosed every four weeks for three doses) in healthy adults. It derives a 40 mg subcutaneous starting dose from an assumed 13-week cynomolgus monkey no-observed-adverse-effect level of 50 mg/kg/week, a maximum recommended starting dose of about 350 mg, and a further 8.75-fold margin, escalating by doubling to 320 mg with sentinel dosing and Safety Review Committee review. The synopsis covers 48 planned participants (up to 58 with replacements), pharmacokinetic, pharmacodynamic, and immunogenicity endpoints, dose-limiting rules, a schedule of events, and a descriptive statistical analysis. The article corrects a common labeling error, describing a doubling schedule as half-log, and states which values are assumptions.Keywords: first-in-human; monoclonal antibody; APRIL; single ascending dose; multiple ascending dose; maximum recommended starting dose; ICH S6(R1); sentinel dosing

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426497
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a Phase 1 Single- and Multiple-Ascending-Dose Study of a Humanized Anti-APRIL Monoclonal Antibody in Healthy Adults: Starting-Dose Derivation, Escalation, and Protocol Synopsis

Peivand Pirouzi, Patricia Angelique Mallari
Zenodo (CERN European Organization for Nuclear Research)
Monoclonal and Polyclonal Antibodies Research
article

Designing a Phase 1 Single- and Multiple-Ascending-Dose Study of a Humanized Anti-APRIL Monoclonal Antibody in Healthy Adults: Starting-Dose Derivation, Escalation, and Protocol Synopsis

Peivand Pirouzi, Patricia Angelique Mallari
article en

Abstract

A humanized antibody that neutralizes a proliferation-inducing ligand (APRIL) is designed to reduce pathogenic immunoglobulin production in B-cell-driven diseases, and its first-in-human study must show that the starting dose sits well below any dose that could cause harm to a healthy volunteer. This article develops a hypothetical Phase 1 randomized, double-blind, placebo-controlled study with a single-ascending-dose part (four cohorts) and a multiple-ascending-dose part (two cohorts dosed every four weeks for three doses) in healthy adults. It derives a 40 mg subcutaneous starting dose from an assumed 13-week cynomolgus monkey no-observed-adverse-effect level of 50 mg/kg/week, a maximum recommended starting dose of about 350 mg, and a further 8.75-fold margin, escalating by doubling to 320 mg with sentinel dosing and Safety Review Committee review. The synopsis covers 48 planned participants (up to 58 with replacements), pharmacokinetic, pharmacodynamic, and immunogenicity endpoints, dose-limiting rules, a schedule of events, and a descriptive statistical analysis. The article corrects a common labeling error, describing a doubling schedule as half-log, and states which values are assumptions.Keywords: first-in-human; monoclonal antibody; APRIL; single ascending dose; multiple ascending dose; maximum recommended starting dose; ICH S6(R1); sentinel dosing

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon